Director International Business Analytics
Viridian Therapeutics
Director International Business Analytics
Viridian Therapeutics
Develops miRNA-targeting therapies for autoimmune diseases
At Viridian, we work with a sense of urgency for patients, creating unity with our team, the industry, and the community. We are committed to using proven science and engineering to improve the lives of people living with serious and rare diseases, and we are getting closer to achieving this goal every day.
Reporting to the Vice President, International, the Director/Senior Director International Business Analytics will be accountable for market insight development, competitive intelligence, forecasting, analytics, and market assessments across International markets.
This role will be responsible for informing, challenging and tracking international strategies and execution, across launch readiness, and in-market performance for two Phase 3 assets, providing critical insights and analytics to inform key decisions with significant financial, organizational, and multi-year business impact.
Operating as part of the International Leadership Team and partnering closely with cross-functional leaders, this role will engage across priority launch markets to create a launch platform for the successful commercialization of the Viridian portfolio.
A close partnership with US/Global Commercial Effectiveness & Planning (Market Research, Forecasting, Analytics and Competitive Intelligence) will be critical. Within the International team structure this role will develop key partnerships with International Commercial Operations & Marketing, International Medical Affairs and International Market Access & Government Affairs to align strategy to drive differentiation and adoption in priority markets. This is a foundational role with significant responsibility for shaping Viridian’s international capabilities from launch planning through commercialization and lifecycle management. This position will be based in the UK.
Responsibilities (including, but not limited to):
Collaboration & Governance:
Requirements:
Applicant Privacy Notice: Information submitted in connection with your application will be processed in accordance with Viridian's Privacy Policy, available here.
Develops miRNA-targeting therapies for autoimmune diseases
Viridian Therapeutics discovers and develops therapies that target microRNA (miRNA) pathways to treat autoimmune diseases, with a focus on thyroid eye disease. The company uses monoclonal antibody technology aimed at the IGF-1 receptor (IGF-1R) pathway to modulate disease biology. Its product approach integrates miRNA biology with antibody engineering to create treatments that intervene in autoimmune processes. The company differentiates itself by combining miRNA-targeting strategies with IGF-1R–focused monoclonal antibodies, operating in the clinical-stage space and concentrating on rare thyroid-related autoimmune conditions. Its goal is to advance clinical candidates through development toward regulatory approval and eventual market launch for patients who suffer from these diseases.
Explore more opportunities at Viridian Therapeutics